Report Description Table of Contents Introduction And Strategic Context The Global Age-Related Macular Degeneration (AMD) Market is projected to grow at a 6.8% CAGR, rising from $9.4 billion in 2024 to nearly $14.0 billion by 2030, driven by anti-VEGF therapies, aging population, and retinal innovation, confirms Strategic Market Research. Age-related macular degeneration (AMD) is a progressive eye disease that primarily affects the elderly, leading to central vision loss due to damage in the macula—the central part of the retina. The condition is becoming increasingly prevalent as global life expectancy rises. With a rapidly aging population and greater diagnostic awareness, AMD has emerged as a major area of concern in ophthalmology. Technological innovations, such as biologic therapeutics, anti-VEGF agents, retinal implants, and home-based diagnostic tools, are accelerating both detection and treatment options in 2024. The global burden of vision impairment is shifting dramatically, with AMD contributing significantly to irreversible visual decline in high-income countries, note ophthalmic research experts. As the prevalence of AMD rises, healthcare systems are being compelled to enhance diagnostic access and subsidize long-term treatment regimens. Several macroeconomic and sector-specific forces are shaping the AMD landscape: Demographic Shifts: Over 1.5 billion people will be aged 65 or older by 2050, directly contributing to AMD incidence. Innovation in Therapeutics: Anti-VEGF therapies have transformed the wet AMD treatment paradigm, with biosimilars and gene therapies on the horizon. Healthcare Access and Reimbursement: Payer policies and reimbursement frameworks in Europe and North America play a crucial role in therapy access and adoption. Digital Health Integration: Tele-retinal imaging and AI-based fundus interpretation are improving early detection and patient engagement. Public Health and Regulatory Focus: National vision care programs and patient registries are enhancing surveillance and longitudinal data capture. Key stakeholders in this market include: Biopharmaceutical manufacturers (developing biologics, biosimilars, and gene therapies) Ophthalmology clinics and hospitals (frontline treatment and diagnostic hubs) Diagnostic equipment providers (OCT, fundus imaging, and AI systems) Government agencies and non-profits (implementing screening programs and funding awareness) Private insurers and public health authorities (reimbursement and care model innovators) Venture capital and private equity investors (funding next- gen therapy developers) As AMD continues to impose clinical and economic burdens, strategic focus is shifting towards integrated care delivery, disease-modifying therapies, and preventive diagnostics. This report offers a comprehensive, forward-looking view of how the AMD market will evolve between 2024 and 2030. Comprehensive Market Snapshot The Global Age-Related Macular Degeneration (AMD) Market will witness a robust CAGR of 6.8%, valued at approximately $9.4 billion in 2024, and is expected to appreciate and reach nearly $14.0 billion by 2030. The USA Age-Related Macular Degeneration (AMD) Market, accounting for 31% of global revenue, will register a healthy 6.3% CAGR, expanding from approximately $2.9 billion in 2024 to around $4.2 billion by 2030. The Europe Age-Related Macular Degeneration (AMD) Market, representing 26% market share, will grow at a moderate 4.5% CAGR, increasing from about $2.4 billion in 2024 to nearly $3.2 billion by 2030. The Asia-Pacific (APAC) Age-Related Macular Degeneration (AMD) Market, holding 17% of global share, is projected to be the fastest-growing region, advancing at an 8.3% CAGR and expanding from approximately $1.6 billion in 2024 to around $2.6 billion by 2030, driven by aging demographics, improving diagnosis rates, and expanding access to anti-VEGF therapies. Market Segmentation Insights By Disease Type Wet AMD held the largest share of the global AMD market at approximately 64% in 2024, reflecting its high treatment intensity and dependence on chronic anti-VEGF regimens, with an estimated market value of around USD 6.02 billion. Dry AMD, despite accounting for nearly 80–85% of diagnosed AMD cases, represented about 36% of market value in 2024, translating to approximately USD 3.38 billion. The segment is projected to grow at a notable CAGR during 2024–2030, supported by the emergence of complement inhibitors and disease-modifying pipeline therapies targeting geographic atrophy. By Drug Class Anti-VEGF agents dominated the AMD therapeutic landscape with approximately 72% market share in 2024, corresponding to an estimated value of around USD 6.77 billion, driven by repeat dosing requirements, established physician trust, and broad reimbursement coverage. Complement inhibitors accounted for about 14% of the market in 2024, valued at approximately USD 1.32 billion, and are expected to grow at the fastest CAGR through 2024–2030, supported by late-stage clinical programs addressing dry AMD progression. Gene therapy candidates represented nearly 8% share in 2024, translating to an estimated market size of around USD 0.75 billion, reflecting early commercial uptake, limited patient eligibility, and high per-procedure pricing. Others (including antioxidants, corticosteroids, and lifestyle-oriented therapies) collectively held about 6% of the market in 2024, valued at approximately USD 0.56 billion, primarily supporting adjunctive and preventive management rather than disease modification. By Route of Administration Intravitreal administration remained the dominant delivery route, accounting for approximately 78% of the global market in 2024, equivalent to around USD 7.33 billion, due to its central role in anti-VEGF therapy delivery. Oral therapies captured about 10% share in 2024, translating to an estimated value of approximately USD 0.94 billion, supported by patient preference for non-invasive options and early complement-inhibitor formulations. Subretinal delivery represented roughly 8% of the market in 2024, valued at around USD 0.75 billion, and is expected to grow at a strong CAGR through 2030, driven by gene and cell therapy development. Others accounted for the remaining 4% share, corresponding to approximately USD 0.38 billion, including experimental and combination delivery approaches. By Distribution Channel Hospital pharmacies dominated AMD drug distribution with approximately 61% market share in 2024, reflecting physician-administered biologics and controlled storage requirements, equivalent to an estimated USD 5.73 billion. Retail pharmacies accounted for about 22% of the market in 2024, translating to approximately USD 2.07 billion, supported by oral adjunct therapies and follow-up prescription fulfillment. Online pharmacies captured nearly 17% share in 2024, valued at approximately USD 1.60 billion, and are forecast to grow at the highest CAGR during 2024–2030, driven by e-prescriptions, specialty logistics, and chronic refill demand in developed markets. Strategic Questions Driving the Next Phase of the Global Age-Related Macular Degeneration (AMD) Market What disease stages, subtypes (dry vs. wet AMD), and treatment modalities are explicitly included within the AMD market definition, and which vision-care interventions fall outside its commercial scope? How does the AMD market differ structurally from adjacent ophthalmology segments such as diabetic retinopathy, retinal vein occlusion, and inherited retinal diseases? What is the current and forecasted size of the global AMD market, and how is total value distributed between dry AMD and wet AMD therapeutic segments? How is revenue allocated across anti-VEGF therapies, emerging complement inhibitors, gene therapies, and supportive treatments, and how is this mix expected to evolve through 2030? Which disease segments (neovascular AMD, geographic atrophy, early/intermediate dry AMD) represent the largest and fastest-growing revenue pools? Which AMD therapy segments generate disproportionate profitability relative to patient volume, particularly considering treatment frequency, duration, and pricing dynamics? How does demand differ across early-stage, intermediate, and advanced AMD populations, and how does this stratification influence therapy selection and sequencing? How are first-line anti-VEGF regimens, extended-interval dosing strategies, and next-generation therapies reshaping standard AMD treatment pathways? What role do injection frequency, treatment persistence, discontinuation rates, and therapy switching play in long-term revenue sustainability within the AMD market? How are disease prevalence, aging demographics, screening penetration, and diagnostic access shaping treated-patient expansion across regions? What clinical, logistical, or adherence-related constraints limit adoption of advanced AMD therapies, particularly in elderly and mobility-restricted populations? How do pricing pressure, reimbursement frameworks, and payer utilization controls affect revenue realization across branded biologics, biosimilars, and emerging therapies? How strong is the current AMD development pipeline, and which mechanisms of action (e.g., complement modulation, gene therapy, regenerative approaches) are most likely to create new commercial segments? To what extent will pipeline assets expand the treated AMD population versus intensify competition within existing wet and dry AMD segments? How are formulation innovations and drug-delivery technologies (long-acting injectables, subretinal delivery, sustained-release platforms) reducing treatment burden and improving patient adherence? How will patent expirations and loss of exclusivity among leading anti-VEGF agents reshape competitive dynamics and pricing structures? What role will biosimilars play in accelerating access, driving price erosion, and altering prescribing behavior across global AMD markets? How are leading pharmaceutical and biotechnology companies aligning their AMD portfolios to balance lifecycle management, innovation risk, and market defense? Which geographic regions are expected to outperform global AMD market growth, and which disease or therapy segments are driving regional outperformance? How should manufacturers, investors, and healthcare systems prioritize specific AMD segments, technologies, and regions to maximize long-term clinical and economic value? Segment-Level Insights and Market Structure - Age-Related Macular Degeneration (AMD) Market The Age-Related Macular Degeneration (AMD) market is structured around distinct disease phenotypes, therapeutic classes, delivery routes, and distribution settings that reflect differences in disease progression, treatment intensity, and long-term patient management. Each segment contributes differently to overall market value, competitive dynamics, and future growth opportunities, shaped by chronic treatment needs, aging demographics, and evolving retinal care models. Disease Type Insights Dry AMD Dry AMD represents the most prevalent form of the disease, accounting for the majority of diagnosed cases globally. Clinically, it is characterized by gradual retinal degeneration and slower progression, often managed through monitoring, lifestyle interventions, and supportive therapies. From a market perspective, dry AMD has historically generated lower pharmaceutical revenue due to the absence of widely adopted disease-modifying treatments. However, its large untreated population base makes it a strategically important segment. Ongoing advances in complement inhibition and inflammation-targeted therapies are expected to gradually elevate its commercial relevance over the forecast period. Wet AMD Wet AMD is a less common but significantly more severe form of the disease, associated with rapid vision loss and high treatment urgency. It dominates market value due to the need for continuous, high-frequency pharmacologic intervention. Commercially, wet AMD is the most monetizable segment, driven by long-term use of injectable therapies and sustained patient follow-up. Its revenue contribution is reinforced by established treatment protocols and strong reimbursement support, making it the economic backbone of the AMD market through 2030. Drug Class Insights Anti-VEGF Agents Anti-VEGF therapies form the cornerstone of wet AMD management and represent the most established and widely prescribed drug class in the market. Their effectiveness in controlling abnormal blood vessel growth has made them central to standard care. From a commercial standpoint, this segment benefits from repeat dosing, long treatment duration, and strong clinician familiarity. Although competition is increasing with biosimilar entry, anti-VEGF agents are expected to retain a dominant position due to entrenched clinical reliance and proven outcomes. Complement Inhibitors Complement inhibitors are an emerging and strategically significant drug class, particularly for dry AMD. These therapies aim to slow disease progression by targeting inflammatory and immune pathways implicated in retinal degeneration. While adoption is still developing, this segment represents a key innovation frontier within the AMD market. As late-stage candidates advance toward broader clinical use, complement inhibitors are expected to reshape the treatment landscape for previously underserved patient populations. Gene Therapy Candidates Gene therapy approaches represent a high-innovation, long-term potential segment within the AMD market. These therapies are designed to provide sustained therapeutic benefit through single or limited administrations. Although currently limited to select patient groups and specialized treatment centers, gene therapies introduce a fundamentally different value proposition focused on durability rather than chronic dosing. Their commercial impact is expected to expand gradually as clinical experience, regulatory clarity, and delivery platforms mature. Others Other therapeutic approaches, including antioxidants, corticosteroids, and supportive pharmacologic interventions, play an adjunctive role in AMD management. These treatments primarily address symptom support or secondary complications rather than disease modification. While their contribution to total market value is modest, they remain relevant for early-stage disease management and supportive care strategies. Route of Administration Insights Intravitreal Intravitreal administration is the dominant delivery route in the AMD market, particularly for biologic therapies. It is closely integrated into clinical practice, supported by standardized procedures and specialist-led care. Despite patient burden associated with frequent injections, this route remains the preferred method due to its proven efficacy and localized drug delivery. Oral Oral therapies represent a developing segment aimed at improving convenience and adherence, especially for chronic disease management. While currently limited in scope, oral delivery is gaining interest as new mechanisms are explored, particularly for dry AMD and systemic modulation strategies. Subretinal Subretinal delivery is primarily associated with advanced therapies such as gene and cell-based treatments. This route is more invasive and typically restricted to specialized centers, but it enables targeted retinal intervention. Over time, improvements in surgical techniques and delivery systems are expected to support broader adoption. Others Other administration routes remain largely experimental or supportive in nature, contributing marginally to current market value but serving as potential platforms for future innovation. Segment Evolution Perspective The AMD market is transitioning from a landscape dominated by chronic injectable therapies toward a more diversified structure that includes disease-modifying, long-acting, and potentially curative approaches. While wet AMD therapies continue to anchor near-term revenue, innovation in dry AMD and advanced delivery platforms is expected to rebalance value distribution over time. Simultaneously, shifts toward outpatient care, digital access, and reduced treatment burden are reshaping how therapies are delivered and commercialized across segments. Market Segmentation And Forecast Scope The age-related macular degeneration market is segmented comprehensively to reflect the evolving landscape of disease types, therapeutic modalities, patient settings, and regional adoption patterns. The segmentation approach for this report is as follows: By Disease Type Dry AMD Wet AMD Dry AMD currently accounts for the largest share of diagnosed cases globally, constituting around 80–85% of all AMD cases . However, due to the absence of approved disease-modifying treatments, the market value remains significantly lower than that of Wet AMD , which drives the majority of therapeutic revenues through anti-VEGF regimens. While dry AMD is more prevalent, wet AMD dominates pharmaceutical sales due to ongoing therapy needs, making it the most monetizable segment through 2030. By Drug Class Anti-VEGF Agents Complement Inhibitors Gene Therapy Candidates Others (e.g., antioxidants, corticosteroids, lifestyle drugs) Anti-VEGF agents are the cornerstone of wet AMD management and are expected to maintain dominance in 2024. Notably, biosimilars are beginning to disrupt branded monopolies, offering cost-effective alternatives. The complement inhibitor class is gaining traction for dry AMD, with pipeline candidates targeting geographic atrophy and inflammation-driven progression. The fastest-growing segment by 2030 is expected to be complement inhibitors, owing to multiple Phase III trials entering commercialization and regulatory pathways across the U.S., EU, and Japan. By Route of Administration Intravitreal Oral Subretinal Others Intravitreal injection remains the gold standard for delivering anti-VEGF agents, but oral and subretinal delivery platforms are emerging, particularly in gene and cell therapy modalities. These methods aim to reduce injection burden and improve patient compliance. By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Hospital pharmacies held the dominant share in 2024 due to the need for administered biologics and specialized handling. However, online pharmacies are growing rapidly, especially in developed markets, facilitated by prescription digitization and chronic refill demand. By Region North America Europe Asia Pacific LAMEA (Latin America, Middle East, and Africa) Each of these regions presents distinct regulatory, clinical, and infrastructural dynamics. While North America leads in terms of revenue and innovation, Asia Pacific is expected to experience the fastest CAGR through 2030 , driven by a swelling elderly population and increasing public-private vision care initiatives. Market Trends And Innovation Landscape The age-related macular degeneration (AMD) market is experiencing a transformative phase, driven by the convergence of biologics innovation, AI-enabled diagnostics, gene therapy pipelines, and payer-driven value models. 2024 is shaping up to be a pivotal year in AMD innovation, with several paradigm-shifting trends unfolding across the clinical and commercial spectrum. 1. Advanced Biologics and Biosimilars Entering Mainstream Anti-VEGF therapies such as aflibercept and ranibizumab have long dominated the wet AMD treatment space. However, the expiration of exclusivity patents has opened the doors for biosimilars , which are reshaping the pricing and access dynamics globally. Leading manufacturers are diversifying their portfolios with long-acting formulations, reduced injection frequency, and refillable ocular implant systems. “Next-gen anti-VEGF biologics with 12– 16 week durability windows are dramatically reducing the injection burden, leading to better adherence and cost containment,” says a retinal specialist at a Boston-based eye institute. 2. AI and Home-Based Diagnostics Reshaping Monitoring Models The deployment of artificial intelligence (AI) in AMD diagnostics is accelerating. AI-powered platforms for optical coherence tomography (OCT) interpretation are enabling earlier disease detection and precise monitoring of progression. Home-based tools, including tele-ophthalmology apps and self-operated vision monitoring devices , are being trialed in high-risk elderly cohorts to minimize travel and enable real-time alerts. Smart home-based AMD monitoring is becoming a reality, not a vision—reducing clinic visits and detecting fluid accumulation before symptoms emerge. 3. Gene and Cell Therapy Pioneers Advancing Phase II/III Trials Biopharma R&D is now focusing on gene therapy candidates for wet AMD and complement cascade inhibitors for dry AMD (especially geographic atrophy). Adeno-associated virus (AAV)-based delivery systems are being engineered to provide a single-dose, potentially lifelong therapeutic effect . Meanwhile, cell-based regeneration using retinal pigment epithelial (RPE) cells is gaining traction in Japan, South Korea, and select EU centers . If successful, these therapies could end the recurrent injection era and set a new benchmark in AMD management. 4. Industry Collaboration & Licensing Deals There’s been a marked uptick in strategic alliances , co-development deals , and tech licensing agreements between biotech firms and established pharma. These deals aim to de-risk pipeline progression, gain early market access, and co-commercialize high-value molecules. Noteworthy partnerships include tie-ups between ophthalmic biotech startups and global giants to accelerate clinical-stage programs. 5. Imaging and AI Equipment Integration Leading ophthalmic imaging vendors are embedding AI analytics into diagnostic hardware , allowing autonomous disease classification and predictive modeling . OCT angiography is being paired with real-time fluid analysis tools, enhancing diagnostic yield and decision-making efficiency for clinicians. Competitive Intelligence And Benchmarking The age-related macular degeneration (AMD) market is a highly competitive and innovation-driven landscape, dominated by global pharmaceutical giants, niche ophthalmology specialists, and emerging biotech startups . Companies are fiercely competing across multiple fronts—therapy efficacy, injection frequency, market access, biosimilar pricing, and pipeline depth. Below is a benchmarking overview of key players in 2024: 1. Regeneron Pharmaceuticals A dominant force in the wet AMD space, Regeneron continues to lead with its flagship anti-VEGF therapy, supported by a strong lifecycle management strategy. Its extended-dosing formulations and real-world effectiveness data have reinforced physician loyalty. The company has also invested in home-based vision monitoring and digital support platforms, expanding its footprint beyond therapeutics. 2. Roche Holding AG Roche , via its Genentech division, remains a top-tier competitor with robust biologic assets and a growing biosimilar defense strategy. The company has entered 2024 with next-gen delivery platforms and co-formulation trials aiming to simplify administration protocols. Additionally, it’s actively exploring AI-integrated diagnostics as adjuncts to its treatment offering. 3. Novartis AG Novartis is advancing in both wet and dry AMD domains through its ophthalmology franchise. It’s leveraging internal development and licensing deals to enhance its pipeline diversity. The firm is investing heavily in complement inhibition therapy for geographic atrophy, and collaborating with AI firms for predictive disease progression tools. 4. Apellis Pharmaceuticals An emerging disruptor in the dry AMD segment, Apellis has made significant progress in commercializing complement system inhibitors targeting geographic atrophy. With novel targets and differentiated delivery routes, it’s attracting both investor confidence and early adoption interest among retinal specialists. 5. Bayer AG Bayer has established itself as a European AMD leader, particularly through co-marketing and development partnerships in the anti-VEGF space. The company is actively investing in slow-release depot systems and has recently expanded into the Asia-Pacific ophthalmology market via regional alliances. 6. Iveric Bio (An Astellas Company) Recently acquired by Astellas, Iveric Bio is at the forefront of R&D for dry AMD treatments. Its proprietary complement factor inhibitors are in advanced clinical stages and show promise in reducing the rate of geographic atrophy progression. Its acquisition signals increasing consolidation in the AMD innovation chain. 7. Outlook Therapeutics Focusing specifically on ophthalmic biosimilars, Outlook Therapeutics is working toward regulatory approvals for bevacizumab ophthalmic formulations. Its strategy is aimed at increasing affordability and access, particularly in emerging markets and underfunded healthcare systems. These companies vary widely in strategy: while larger incumbents dominate on scale and global reach, smaller innovators are pushing boundaries in dry AMD and regenerative approaches. The competitive outlook for 2025–2030 will likely hinge on gene therapy approvals , durable formulations , and cost-effective biosimilar penetration . Regional Landscape And Adoption Outlook The age-related macular degeneration (AMD) market exhibits distinct regional variations in disease prevalence, reimbursement models, clinical infrastructure, and treatment access. While North America and Europe currently lead in terms of revenue and innovation, Asia Pacific and parts of Latin America and the Middle East are emerging as high-potential growth territories driven by demographic shifts and expanding ophthalmic care networks. North America North America, particularly the United States , dominates the global AMD market due to: Early adoption of biologics and biosimilars Strong ophthalmology referral networks High per capita healthcare expenditure Robust Medicare and private payer coverage for anti-VEGF injections The U.S. also has an advanced diagnostic landscape, with AI-assisted imaging , OCT devices , and retinal gene therapy centers concentrated in academic hubs. “In the U.S., frequency and access are no longer the main challenge—it’s about optimizing outcomes and reducing clinic burden,” notes a senior ophthalmologist at Johns Hopkins. Canada mirrors these trends, though access disparities persist between urban and remote populations. Europe Europe is a mature AMD market with considerable variation by country: Germany , France , and the UK have strong biosimilar integration and public reimbursement for AMD therapies. Scandinavian countries lead in integrating AI-based home diagnostics into public health frameworks. Eastern Europe , while improving, still faces gaps in biologic access and imaging infrastructure. The European Medicines Agency (EMA) is actively reviewing advanced therapies, including gene-based solutions, giving Europe an edge in regulatory receptiveness. Asia Pacific The Asia Pacific region is poised to record the fastest growth rate through 2030. Key growth drivers include: Rapidly aging populations in China , Japan , and South Korea Expanding healthcare infrastructure and government vision health campaigns Rising adoption of AI and mobile screening in rural and semi-urban areas Japan is a leader in regenerative medicine applications, having approved several cell-based AMD treatments. China is investing heavily in AI diagnostics and low-cost biosimilars to scale nationwide AMD management. In China, community vision clinics with AI screening software are being deployed in Tier 2 and Tier 3 cities, signaling a mass decentralization of AMD diagnostics. Latin America, Middle East & Africa (LAMEA) These regions are in the nascent stages of AMD market development, but show promising indicators: Brazil and Mexico have active public-private programs for retinal disease awareness and imaging access. Saudi Arabia and the UAE are investing in specialized ophthalmic hospitals and bringing in advanced therapies through partnerships with European suppliers. Africa remains largely underserved, with AMD diagnosis rates far below global averages, although pilot programs in South Africa are making headway. White Space Opportunity : Rural India, Sub-Saharan Africa, and inland Latin America lack consistent access to retinal specialists or OCT imaging. These are long-term penetration markets for portable diagnostics and biosimilar therapeutics. End-User Dynamics And Use Case The demand and utilization of AMD therapies and diagnostics are deeply influenced by the type of end user, each of which plays a distinct role in the treatment journey. End-user preferences often shape procurement patterns, therapeutic adoption rates, and integration of digital tools. The key end users in the age-related macular degeneration market include: 1. Hospitals and Specialized Ophthalmology Centers Large hospitals and vision-focused centers are the primary treatment hubs for wet AMD. These facilities typically have advanced imaging infrastructure such as OCT , OCT-Angiography , and fluorescein angiography , and are authorized for intravitreal biologic administration. Hospitals also serve as principal nodes for clinical trials and early adoption of novel therapies , such as gene and cell therapies. These centers often run multidisciplinary vision care programs, involving retinal surgeons, low-vision specialists, and rehabilitation services—creating a comprehensive AMD care ecosystem. 2. Ambulatory Surgical Centers (ASCs) While less common in AMD management than cataract surgery, ASCs are beginning to participate in the delivery of longer-acting biologic injections and investigational therapies in select countries like the U.S., Japan, and Germany. Their lower cost and higher throughput make them suitable for routine monitoring and follow-up diagnostics in stable AMD cases. 3. Retail Clinics and Optometry Chains In mature markets like the U.S., optometry chains such as Vision Source and Specsavers have begun offering initial AMD screenings , especially for dry AMD. Though they do not treat advanced disease, their role in referral generation and public education is growing. The optometry channel is becoming an educational and diagnostic front line, particularly for catching early-stage dry AMD in patients with no symptoms. 4. Research Institutions and Academic Hospitals Leading academic hospitals are crucial for R&D in gene therapies , complement inhibitors , and regenerative cell implants . These centers drive early-stage adoption and often publish real-world data (RWD) that guides national treatment protocols. Use Case Scenario: South Korean Tertiary Hospital A tertiary care hospital in Seoul initiated a hybrid AMD management program integrating home-based AI vision tracking tools with hospital-administered anti-VEGF therapy. Elderly patients diagnosed with wet AMD were provided with smartphone-enabled retinal self-assessment kits. If anomalies were detected—such as increased distortion or brightness variation—an automated alert triggered an in-person OCT exam at the hospital. The result: unnecessary injections were reduced by 28%, while disease progression was caught earlier in 19% of cases. Hospital burden decreased, and patients reported higher satisfaction with personalized, proactive care. Recent Developments + Opportunities & Restraints Recent Developments (Last 2 Years) FDA Approval of Pegcetacoplan (Syfovre) for Geographic Atrophy (2023) Apellis Pharmaceuticals secured FDA approval for pegcetacoplan , the first-ever treatment targeting geographic atrophy due to dry AMD. Iveric Bio’s Zimura Gains Breakthrough Therapy Designation (2023): The U.S. FDA granted breakthrough therapy status to Zimura , a complement C5 inhibitor, for geographic atrophy treatment. Roche Launched Vabysmo ® With Dual-Action Mechanism (2022–2023): Roche introduced a new biologic, Vabysmo , offering VEGF and Ang-2 inhibition for wet AMD, promising fewer injections. Samsung Medical Center Rolls Out AI-Based AMD Screening Tool (2024): South Korea’s Samsung Medical Center deployed a national AI-enabled screening initiative for early AMD detection via fundus imaging. Astellas Completes $5.9B Acquisition of Iveric Bio (2023): Astellas finalized its acquisition to deepen its retinal disease portfolio, especially in the dry AMD segment. Opportunities Unmet Need in Dry AMD Treatments: Geographic atrophy remains one of the few irreversible and largely untreated eye conditions—paving the way for massive demand for approved therapies and regenerative options. Integration of AI in Diagnostics and Remote Monitoring: AI-enabled OCT interpretation, tele-screening, and self-monitoring apps offer cost-saving solutions for overloaded healthcare systems and rural outreach. Growth of Biosimilars in Emerging Markets: With biologics driving high treatment costs, biosimilar expansion across Asia, Latin America, and Eastern Europe presents a scalable affordability solution . Restraints High Cost of Biologic and Gene Therapies: Even with biosimilar entry, long-term anti-VEGF treatment costs and single-dose gene therapies remain a barrier to widespread adoption, particularly in underfunded systems. Complex Regulatory Pathways for Novel Therapies: Gene and cell therapies for AMD face extended approval timelines due to safety concerns and post-marketing surveillance demands, delaying market entry. Report Coverage Table Report Attribute Details Forecast Period 2024 – 2030 Market Size Value in 2024 USD 9.4 Billion Revenue Forecast in 2030 USD 14.0 Billion Overall Growth Rate CAGR of 6.8% (2024 – 2030) Base Year for Estimation 2024 Historical Data 2019 – 2023 Unit USD Million, CAGR (2024 – 2030) Segmentation By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography By Disease Type Dry AMD, Wet AMD By Drug Class Anti-VEGF Agents, Complement Inhibitors, Gene Therapy, Others By Route of Administration Intravitreal, Oral, Subretinal, Others By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., UK, Germany, China, Japan, India, Brazil, UAE, etc. Market Drivers - Aging Population - Innovation in Biologics & AI Diagnostics - Expanding Reimbursement Models Customization Option Available upon request Frequently Asked Question About This Report Q1: How big is the age-related macular degeneration market? A1: The global AMD market was valued at USD 9.4 billion in 2024. Q2: What is the CAGR for AMD during the forecast period? A2: The AMD market is projected to grow at a CAGR of 6.8% from 2024 to 2030. Q3: Who are the major players in the AMD market? A3: Leading companies include Regeneron, Roche, Novartis, Apellis, and Bayer. Q4: Which region dominates the AMD market? A4: North America dominates due to robust treatment access and innovation. Q5: What factors are driving the AMD market? A5: Growth is fueled by aging demographics, AI-based diagnostics, and therapy innovations. Executive Summary Market Overview Market Attractiveness by Disease Type, Drug Class, Route of Administration, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Future Projections (2019–2030) Summary of Market Segmentation by Disease Type, Drug Class, Route, Distribution Channel, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share by Drug Class, Route of Administration, and Region Investment Opportunities in the AMD Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Collaborations High-Growth Segments and Emerging Therapy Areas Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Major Investment Zones Research Methodology Overview of Research Process Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Market Dynamics Key Market Drivers Challenges and Restraints Emerging Opportunities for Stakeholders Behavioral , Technological, and Regulatory Impact Analysis Global AMD Market Breakdown By Disease Type Dry AMD Wet AMD By Drug Class Anti-VEGF Agents Complement Inhibitors Gene Therapy Candidates Others By Route of Administration Intravitreal Oral Subretinal Others By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Region North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis (with Country-Level Details) North America U.S. Canada Europe Germany France UK Rest of Europe Asia-Pacific China Japan India South Korea Rest of Asia-Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa UAE Saudi Arabia South Africa Rest of MEA Competitive Intelligence Company Benchmarking and Positioning Matrix Company Profiles: Regeneron Pharmaceuticals Roche Novartis Apellis Pharmaceuticals Bayer AG Iveric Bio Outlook Therapeutics Appendix Acronyms and Terminologies References and Cited Sources List of Tables Market Size by Segment (2024–2030) Regional Market Size by Drug Class and Distribution Channel List of Figures AMD Market Dynamics (Drivers, Restraints, Opportunities) Regional Growth Outlook Competitive Landscape Visualization Market Share Trends by Therapy Type (2024 vs. 2030)